Supplemental figure 11. Kaplan-Meier survival analyses demonstrating no difference in PFS in p53abn EC patients with endometrioid tumors compared to non-endometrioid tumors (carcinosarcoma, clear cell, serous and other) once adjusting for FIGO stage.
No takes yet. Share an insight, caveat, or question.
Jamieson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: